Inclusion Criteria:  Diagnosis of definite amyotrophic lateral sclerosis according to El Escorial revised criteria Spinal onset ALS with initial weakness in the upper or lower extremity. Diagnosed with ALS within the past 24 months 1-2 point change in pre-slope of the ALSFRS-R at time of enrollment (ratio of drop in score from 48 to the duration in months from onset of weakness) Slow vital capacity greater than or equal to 40% of predicted value Score ≥ 2 for "swallowing" of the ALSFRS-R Score ≥ 2 for "walking" of the ALSFRS-R Able to provide informed consent Stable dose of riluzole or edaravone or no medications Availability of a caregiver for remote administration of tDCS  Exclusion Criteria:  Subject has bulbar onset ALS Any neurological diagnosis other than ALS Psychiatric disorders Any other concomitant disease that affects prognosis of ALS inclusive of systemic disease, cardiovascular disease, hepatic or renal disorder Tracheostomal or noninvasive ventilation for more than 12 hours per day Enrollment in an on-going ALS pharmaceutical trial Subject plans on moving within 3 months.  TMS Exclusion Criteria:  Implanted cardiac pacemaker Metal implants in the head or face Unexplained, recurring headaches History of seizures or epilepsy Currently under medication that could increase motor excitability and lower seizure threshold Skull abnormalities or fractures Concussion within the last 6 months Currently pregnant tDCS Exclusion Criteria: Skin hypersensitivity History of contact dermatitis History of allodynia and/or hyperalgesia Any other skin or scalp condition that could be aggravated by tDCS